Clinical Trial: Xbiotech PT049

Trial Status: Open
Disease Type: Pancreatic
Trial ID Xbiotech PT049
Sponsor ID Xbiotech USA Inc

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

Principal Investigator
Keeran R. Sampat, MD
3 Locations

Locations

Arlington Office

Fairfax Office

Gainesville Office

Learn More About This Trial
Other Relevant Trials
Trial ID CG-745-2-08
Sponsor ID Crystal Genomics

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy

Principal Investigator
M. Adham Salkeni, MD, FRCPC
1 Location
Trial ID C-800-22
Sponsor ID Agenus

“A PHASE II RANDOMIZED, OPEN-LABEL, TRIAL OF NAB-PACLITAXEL + GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (AGEN1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN + IRINOTECAN + OXALIPLATIN (FOLFIRINOX)”

Principal Investigator
M. Adham Salkeni, MD, FRCPC
1 Location